The FDA has rolled out an expedited Investigational New Drug (IND) pilot program intended to reduce bottlenecks in the early process of getting therapies into clinical trials. The IND pilot is part of HHS’s onshoring initiative dubbed Operation TrialBlazer, which aims to compress timelines from discovery into first-in-human studies. The agency says the program uses more risk-proportionate, phase-appropriate judgment and allows some processes usually handled sequentially to run in parallel. However, the regulatory decision standards and review timelines are described as unchanged, meaning the pilot’s effect is focused on submission preparation delays. For sponsors, the question is whether earlier feedback and parallelization meaningfully reduce start-up time compared with alternative international timelines—especially for smaller companies that often struggle with submission capacity.